NLRP3 and familial dilated cardiomyopathy: To further investigate whether p16 accumulation could exacerbate the NLRP3 signalling activation in human, our results showed that compared with higher‐p16‐expressed people, a significant reduction in NLRP3‐ and IL‐1β‐positive areas/cells was observed in individuals with low p16 expression; conversely, a marked elevation of these inflammatory markers was detected in DCM patients (Figure S6A–D).